Scynexis (SCYX) Cash from Financing Activities (2013 - 2026)
Scynexis (SCYX) posted Cash from Financing Activities of $24.0 million for Q1 2026, up 21002.61% on a QoQ basis from -$115000.0 in Q4 2025, and up 270.68% year-over-year from $6.5 million in Q1 2025.
Scynexis (SCYX) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Scynexis' Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $24.0 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 270.68% year-over-year to $24.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.0 million (up 268.58% YoY) and the FY2025 annual result came in at -$14.2 million, down 10094.24% from the prior year.
- Cash from Financing Activities was $24.0 million for Q1 2026 at Scynexis, up from -$115000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $42.1 million in Q2 2022 and bottomed at -$36.6 million in Q2 2023.
- A 5-year average of $1.5 million and a median of $3500.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 9569.01% — and 2025, when it tumbled 93793.33%.
- Scynexis' Cash from Financing Activities stood at -$183000.0 in 2022, then rose by 26.23% to -$135000.0 in 2023, then fell by 14.81% to -$155000.0 in 2024, then gained by 25.81% to -$115000.0 in 2025, then soared by 21002.61% to $24.0 million in 2026.
- Business Quant data shows SCYX's Cash from Financing Activities at $24.0 million in Q1 2026, -$115000.0 in Q4 2025, and $29000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | 24.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.04 Mn |
| Mar 31, 2026 | 24.04 Mn |
| Dec 31, 2025 | -115,000.00 |
| Dec 31, 2025 | -115,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Mar 31, 2025 | -14.08 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -155,000.00 |
| Dec 31, 2024 | -155,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Mar 31, 2024 | -15,000.00 |
| Mar 31, 2024 | -15,000.00 |
| Dec 31, 2023 | -135,000.00 |
| Dec 31, 2023 | -135,000.00 |
| Sep 30, 2023 | 34,000.00 |
| Sep 30, 2023 | 34,000.00 |
| Jun 30, 2023 | -36.64 Mn |
| Jun 30, 2023 | -36.64 Mn |